Cullinan Grows its Pipeline of Portfolio Plays with Eye to Clinical Development Kristen Laguerre2019-02-05T18:06:01+00:00February 5, 2019| Read More
Taiho Pharma, Cullinan Oncology Join Forces on Drug for Lung Cancer Kristen Laguerre2019-02-05T18:06:45+00:00February 5, 2019| Read More
Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute Kristen Laguerre2019-02-05T18:07:53+00:00January 30, 2019| Read More
Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics Kristen Laguerre2018-02-20T08:05:34+00:00February 20, 2018| Read More
Cullinan Oncology Adds Industry Leaders to Board, Bringing Significant Business & Healthcare Acumen Cullinan Oncology Adds Industry Leaders to Board, Bringing Significant Business & Healthcare Acumen Kristen Laguerre2017-11-29T10:12:21+00:00November 29, 2017| Read More
With $150m in its pocket, new cancer startup will turn to CROs to ‘execute faster’ Kristen Laguerre2017-11-03T13:03:18+00:00October 5, 2017| Read More
Cullinan Secures $150M to Build Oncology Portfolio from ‘Diamonds in the Rough’ Kristen Laguerre2017-11-03T13:03:35+00:00October 4, 2017| Read More
Cullinan Oncology Emerges with $150 Million and a Roster of All-Star Biotech Scientists Kristen Laguerre2017-11-03T13:03:50+00:00October 3, 2017| Read More
Cambridge biotech startup raises $150 million to develop cancer drugs Kristen Laguerre2017-11-03T13:04:16+00:00October 3, 2017| Read More
Top scientists and BD execs craft Cullinan, a $150 million R&D portfolio shop focused on cancer Kristen Laguerre2017-11-03T13:04:30+00:00October 3, 2017| Read More
